Research supported by Starr Cancer Consortium awards is reported in the following publications. The Starr Cancer Consortium is funded by the Starr Foundation.
Small-Molecule Inhibitors of SETD8 with Cellular Activity.
Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan.
Profiling Substrates of Protein Arginine N-Methyltransferase 3 with S-Adenosyl-l-methionine Analogues.
Structural biology-based insights into combinatorial readout and crosstalk among epigenetic marks.
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia.
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity.
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence.
Organoid Cultures Derived from Patients with Advanced Prostate Cancer.
Sestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to control mTORC1 signaling.
Molecular Mechanism of Action of Plant DRM De Novo DNA Methyltransferases.
Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA.
A cell engineering strategy to enhance the safety of stem cell therapies.